Bristol-Myers Squibb Co (BMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH10D

Download Sample Report download

Buy the Full ReportStarting from $250

Published on

October 2018

Total pages

314

About the Report

Summary

Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects. The company offers its products across the world to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Bristol-Myers Squibb Co (BMY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Bristol-Myers Squibb Co, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 12

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16

Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 18

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deal Details 31

Asset Purchase 31

AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 31

Venture Financing 33

IFM Tre Raises USD31 Million in Series A Venture Financing 33

Enterome Bioscience Raises USD38.5 Million in Series D Financing 34

TARIS Biomedical Raises USD25 Million in Series B Financing 36

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 38

Cardior Pharma Raises USD16.3 Million in Series A Financing 40

IFM Therapeutics Raises USD27 Million in Series A Financing Round 42

Blade Therapeutics Raises USD27 Million in Series B Financing 43

IFM Therapeutics Raises Funds in Seed Financing Round 45

Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 46

Flexus Biosciences Raises USD25 Million in Series B Venture Financing 47

iPierian Raises USD1 Million in Venture Financing 48

Padlock Therapeutics Raises Funds through Series A Financing 49

Flexus Biosciences Raises USD13 Million in Series A Venture Financing 50

iPierian Raises USD 30 Million In Series A Venture Financing 51

Cormorant Pharma Raises USD 2.6 Million In Venture Financing 53

Cardioxyl Pharma Raises USD 28 Million In Series B Financing 54

Private Equity 55

Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 55

Partnerships 57

Bristol-Myers Squibb and Tsinghua University Enter into Co-Development Agreement 57

Bristol-Myers Squibb and Gritstone Oncology Enter into Research Agreement 58

Clinigen and Bristol-Myers Squibb Enter into Agreement 59

Bristol-Myers Squibb Expands Collaboration with Flatiron Health 60

Advantagene Enters into Agreement with Bristol-Myers Squibb 61

Lupus Therapeutics Enters into Agreement with Bristol-Myers Squibb 62

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 63

Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 64

Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 65

Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 66

Replimune Enters into Co-Development Agreement with Bristol-Myers Squibb 68

Sirenas Enters into Research Agreement wiith Bristol-Myers Squibb 69

Taris Biomedical and Bristol-Myers Squibb Enter into Partnership 70

Bristol-Myers Squibb Enters into Research Agreement with Kumamoto University 71

AbbVie and Bristol-Myers Squibb Enter into Agreement 72

Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 73

Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 74

Bristol-Myers Squibb Enters into Partnership with Novartis 75

Bristol-Myers Squibb and Qiagen Enter into Agreement 76

Advaxis and Bristol-Myers Squibb Enter into Agreement 77

Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 78

Bristol-Myers Squibb Enters into Research Agreement with Transgene 79

Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 80

Bristol-Myers Squibb Enters into Agreement with Apexigen 81

Bristol-Myers Squibb and Incyte Enter into Agreement 82

Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 83

Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 84

Exelixis Enters into Agreement with Bristol-Myers Squibb 85

Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 86

Janssen Biotech Enters into Partnership with Bristol-Myers 87

Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 88

Target Pharma Extends Agreement with Bristol-Myers Squibb 89

Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 90

Bristol-Myers Squibb Expands Agreement with Infinity Pharma 91

Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 92

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 93

GreenPeptide Enters into Agreement with Bristol-Myers Squibb 94

AbbVie and Bristol-Myers Squibb Enter into Agreement 95

Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 96

Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 97

Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 98

Oncodesign Enters into Agreement with Bristol-Myers Squibb 99

Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 100

Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 101

IFM Therapeutics to Enter into Research Agreement with University of Michigan 102

Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 103

Bristol-Myers Squibb Enters into Research Agreement with UCLA 104

Bristol-Myers Squibb Enters into Research Agreement with Princeton University 105

Bristol-Myers Squibb Enters into Research Agreement with NCCN 106

Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 107

Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 108

Bristol-Myers Squibb Enters into Agreement with uniQure 109

Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 110

Bristol-Myers Squibb Enters into Agreement with Eli Lilly 111

Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 112

Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 113

OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 116

Bristol-Myers Squibb Enters into Agreement with Celgene 117

Bristol-Myers Squibb Forms Joint Venture with Allied Minds 118

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 119

Syngene International Extends R&D Agreement with Bristol-Myers Squibb 121

Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 122

Evotec Enters into Agreement with Padlock Therapeutics 123

Evotec Extends Agreement with Padlock Therapeutics 124

Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 125

AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 126

Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 127

Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 128

Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 130

Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 131

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 132

Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 133

Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson's Disease 134

Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 135

Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 136

Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 137

Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 138

Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 139

Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 140

Licensing Agreements 141

Bristol-Myers Enters into Licensing Agreement with Domain Therapeutics 141

Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 142

Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 143

Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 144

Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 145

Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 146

CN Bio Innovations Forms Licensing Agreement with Bristol-Myers Squibb 147

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 148

Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 149

Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 150

Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 151

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 152

Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 153

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 155

Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 156

Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 157

Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 159

Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 160

Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 161

Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 162

Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 163

Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 164

Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 165

Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 166

Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 167

Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 168

Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 169

Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 170

Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 172

Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 174

Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 175

Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 177

Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 179

Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 180

University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 181

Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 182

Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 183

MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 184

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 185

Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 187

Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 188

Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 189

PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 190

PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 191

Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 192

Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 193

Equity Offering 194

Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 194

uniQure Raises USD38 Million in Private Placement of Shares 196

Debt Offering 197

Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 197

Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 199

Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 201

Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 202

Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For USD 500 Million 203

Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For USD 500 Million 205

Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For USD 500 Million 207

Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For USD 500 Million 209

Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For USD 750 Million 211

Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For USD 750 Million 213

Asset Transactions 215

SK Biotek Acquires API Manufacturing Facility from Bristol-Myers Squibb for USD165 Million 215

Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 216

Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 217

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 218

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 219

The CPP Investment Acquires Royalty Rights from Bristol-Myers Squibb 220

R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 221

Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 222

PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 223

Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For USD 750 Million 224

Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 225

Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 226

Acquisition 227

Bristol-Myers Squibb Acquires IFM Therapeutics 227

Bristol-Myers Squibb Acquires Cormorant Pharma 228

Bristol-Myers Squibb Acquires Padlock Therapeutic 229

Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 230

Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 231

Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 233

Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 234

Pfizer May Acquire Bristol-Myers Squibb 235

Bristol-Myers Squibb Acquires iPierian 236

AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For USD 4.3 Billion 237

Bristol-Myers Rumored To Acquire Biogen Idec 239

Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For USD 5.3 Billion 240

Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For USD 2.5 Billion 242

Bristol-Myers Squibb Co - Key Competitors 245

Bristol-Myers Squibb Co - Key Employees 246

Bristol-Myers Squibb Co - Locations And Subsidiaries 248

Head Office 248

Other Locations & Subsidiaries 248

Joint Venture 254

Recent Developments 255

Strategy And Business Planning 255

Nov 01, 2017: Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York 255

Financial Announcements 256

Jul 26, 2018: Bristol-Myers Squibb Reports Second Quarter Financial Results 256

Feb 05, 2018: Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results 258

Oct 26, 2017: Bristol-Myers Squibb Reports Third Quarter Financial Results 260

Jul 27, 2017: Bristol-Myers Squibb Reports Second Quarter Financial Results 262

Apr 27, 2017: Bristol-Myers Squibb Reports First Quarter Financial Results 265

Jan 26, 2017: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results 268

Corporate Communications 271

Aug 28, 2018: Bristol-Myers Squibb names Christopher Boerner as executive vice president and chief commercial officer 271

Jul 23, 2018: Bristol-Myers Squibb announces resignation of Murdo Gordon as Chief Commercial Officer 272

Mar 01, 2018: Bristol-Myers Squibb Names Jose Baselga, M.D., Ph.D. to Board of Directors 273

Oct 09, 2017: Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine 274

Sep 13, 2017: Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors 275

Apr 12, 2017: NICE's draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says 276

Mar 08, 2017: Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer 277

Feb 21, 2017: Bristol-Myers Squibb Appoints Three New Independent Directors 279

Government and Public Interest 280

May 11, 2018: Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer Outcomes 280

May 10, 2018: New Grants Totaling $2.6 Million Fund Work to Reduce Immunotherapy Side Effects 281

May 02, 2018: 2cureX's CEO Ole Thastrup will join Folkemodet 2018 in Denmark 282

Oct 26, 2017: Study to test combination therapy for breast cancer 283

Sep 08, 2017: Major breakthroughs spell hope for melanoma patients 284

Product News 285

12/12/2017: PsiOxus Therapeutics Receives $15M Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA 285

Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 286

10/04/2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program 288

06/14/2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017) 289

06/04/2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting 290

06/03/2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy 291

May 14, 2018: Researchers test flexible cancer research model 293

May 02, 2018: BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace 294

04/20/2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting 295

03/13/2017: Expansion Of Phase I/II Trial Evaluating Lirilumab In Combination With Opdivo (Nivolumab) In Patients With Advanced Solid Tumors 296

Product Approvals 297

Jun 21, 2018: U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden =10 mut/Mb 297

Nov 28, 2017: CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic 298

Jan 24, 2017: European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis 299

Clinical Trials 300

Sep 12, 2018: Bristol-Myers Squibb's novel, oral, selective TYK2 inhibitor delivered significant skin clearance in patients with moderate to severe plaque psoriasis in phase 2 trial 300

Jul 10, 2018: Exalenz Bioscience's Non-Invasive BreathID Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH 302

Oct 20, 2017: Bristol-Myers Squibb to Present New Data on its liver disease drug candidate BMS-986036 at The Liver Meeting 2017 303

Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial 304

Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis 305

Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting 306

Feb 15, 2017: ASLAN Pharmaceuticals' new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine 307

Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 308

Other Significant Developments 309

Aug 07, 2018: Melanoma Research Alliance announces new funding opportunity for research to accelerate progress toward curing melanoma 309

Aug 06, 2018: Scripps Research and Bristol-Myers Squibb scientists create atomic glue gun to build better nucleic acid therapeutics 310

May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 312

Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 313

Appendix 314

Methodology 314

About GlobalData 314

Disclaimer 314

List of Figure

List of Figures

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 14

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16

Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 18

List of Table

List of Tables

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14

Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Bristol-Myers Squibb Co, Deals By Therapy Area, 2012 to YTD 2018 16